Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib plus carboplatin, pemetrexed, and bevacizumab for KRAS G12C-mutant advanced non-squamous non-small cell lung cancer
ACTRN12622000973718Phase 2Active, not recruiting
- Sponsor
- The University of Sydney
- Start
- Sep 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib, pemetrexed, carboplatin and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by The University of Sydney. Primary endpoint: Objective tumour response rate. Started Sep 2022; status: active, not recruiting.
02
Drugs
sotorasibpemetrexedcarboplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12622000973718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000973718.